Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation
oleh: Lucía Barbier-Torres, Karen A. Fortner, Paula Iruzubieta, Teresa C. Delgado, Emily Giddings, Youdinghuan Chen, Devin Champagne, David Fernández-Ramos, Daniela Mestre, Beatriz Gomez-Santos, Marta Varela-Rey, Virginia Gutiérrez de Juan, Pablo Fernández-Tussy, Imanol Zubiete-Franco, Carmelo García-Monzón, Águeda González-Rodríguez, Dhaval Oza, Felipe Valença-Pereira, Qian Fang, Javier Crespo, Patricia Aspichueta, Frederic Tremblay, Brock C. Christensen, Juan Anguita, María Luz Martínez-Chantar, Mercedes Rincón
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2020-07-01 |
Deskripsi
Non-alcoholic fatty liver (NAFLD) disease causes degeneration of the liver, affects about 25% of people globally, and has no approved treatment. Here, the authors show that the therapeutic siRNA-driven silencing of MCJ in the liver is an effective and safe treatment for NAFLD in multiple mouse models.